<DOC>
	<DOCNO>NCT00005898</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine probability engraftment total body irradiation , cyclophosphamide , fludarabine , anti-thymocyte globulin follow HLA nongenotypically identical donor , T-cell deplete hematopoietic cell transplantation patient Fanconi 's anemia . II . Determine incidence acute chronic graft-versus-host disease patient undergoing treatment regimen . III . Determine one-year survival rate patient undergo treatment regimen . IV . Determine toxicity treatment regimen patient . V. Determine incidence relapse patient myelodysplastic syndrome acute myeloid leukemia undergo treatment regimen .</brief_summary>
	<brief_title>Phase I/II Study Total Body Irradiation , Cyclophosphamide , Fludarabine Followed Alternate Donor Hematopoietic Cell Transplantation Patients With Fanconi 's Anemia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Donor bone marrow , peripheral blood , umbilical cord blood process harvest CD34+ cell . Patients receive preparative cytoreductive therapy comprise total body irradiation day -6 ; cyclophosphamide IV 2 hour day -5 -2 ; fludarabine IV 30 minute day -5 -2 ; methylprednisone IV day -5 24 ; anti-thymocyte globulin IV 4-6 hour day -5 -1 ; cyclosporine IV 2 hour every 12 hour ( every 8 hour patient less 40 kg weight ) day -3 180 , taper absence graft-versus-host disease ; hematopoietic cell transplantation day 0 ; filgrastim ( G-CSF ) IV start day 1 continue blood count recover . Patients follow day 60 , 90 , 180 , annually 3 year .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Patients diagnosis Fanconi 's anemia AND Aplastic anemia OR Myelodysplastic syndrome OR Acute leukemia without chromosomal anomaly Aplastic anemia define least one following : Platelet count le 20,000/mm3 Absolute neutrophil count le 500/mm3 Hemoglobin less 8 g/dL Myelodysplastic syndrome multilineage dysplasia With without chromosomal anomaly Hematologic malignancy ( e.g. , acute myeloid leukemia , acute lymphoblastic leukemia , Bcell nonHodgkin 's lymphoma ) No great 30 % blast bone marrow great 5 % blast peripheral blood No active CNS leukemia time transplantation Must HLA A , B , DRB1 identical 1 antigen mismatch relate ( nonsibling ) unrelated bone marrow , peripheral blood , umbilical cord blood donor Prior/Concurrent Therapy Radiotherapy : No prior radiotherapy would preclude total body irradiation Surgery : Not specify Patient Characteristics Performance status : Karnofsky 70100 % OR Lansky 50100 % Hematopoietic : See Disease Characteristics Hepatic : No hepatic failure ( e.g. , coagulopathy ascites ) Renal : Creatinine clearance least 40 mL/min Cardiovascular : Ejection fraction least 45 % Other : No active uncontrolled infection within one week transplantation No malignant solid tumor ( e.g. , squamous cell carcinoma head , neck , cervix ) within 2 year transplantation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>July 2004</verification_date>
</DOC>